2019 Competition Prescription 
World of DTC Marketing
AUGUST 19, 2022
It’s no wonder that voters consistently rank bringing down prescription drug prices and other measures to reduce the cost of care as among Congress’ top priorities. Congress rightly chose to negioate drug prices for Medicare, but prescription drugs are only 10-12% of every healthcare dollar we spend.
World of DTC Marketing
MARCH 1, 2022
Hospitals, physicians, and clinical care made up more than half of the total healthcare spending in 2019. The lack of choice limits competition, which can drive prices higher. According to KFF, “ the cost of health care often prevents people from getting needed care or filling prescriptions. Half of U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
NOVEMBER 16, 2022
Novartis completed the spin-out of Alcon in 2019, separating products like contact lenses and over-the-counter eyedrops from its prescription eye medicines, headed by age-related macular degeneration (AMD) blockbuster Lucentis (ranibizumab), which is partnered with Roche. billion in the first nine months of this year.
World of DTC Marketing
MARCH 17, 2021
Pharma has gone to court again and again to delay generic competition of biologic drugs. One company AbbVie has used the courts to stop competition of its top drug Humira. For 2020, AbbVie’s handing its longtime CEO $24 million in total pay, up from 2019’s $21.6 In fact, Richard Gonzalez, C.E.O.
PM360
FEBRUARY 1, 2024
The landscape is highly competitive with new prescription medications launching worldwide each year. Early shaping of the label during clinical trial design, risk mitigation, and avoiding approval delays are crucial for seizing a competitive advantage.
World of DTC Marketing
OCTOBER 5, 2021
Seventy-nine percent of Americans think the price of prescription drugs is “unreasonable,” according to a 2019 Kaiser Family Foundation poll , and about 9 in 10 say they support the idea of the government negotiating prices. Via Axios “The 10 highest-selling drugs in the U.S.
pharmaphorum
DECEMBER 15, 2022
of total sales – under the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) introduced in 2019. Next year we must start again with a clean sheet of paper to agree on what an internationally competitive scheme looks like.” billion (around $4 billion) in revenue to the government – 26.5% VPAS tax on top. .
Expert insights. Personalized for you.
204 
Let's personalize your content